MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.04
-0.83
-2.88%
Opening 15:24 10/28 EDT
OPEN
28.18
PREV CLOSE
28.87
HIGH
28.18
LOW
26.72
VOLUME
212.30K
TURNOVER
--
52 WEEK HIGH
30.43
52 WEEK LOW
9.01
MARKET CAP
1.55B
P/E (TTM)
-16.7523
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces clinical data at the European Society for Immunodeficiencies (ESID) 2020 Meeting being held virtually October 14-17, 2020. An oral presentation provides positive longer-term follow-up data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster highlights preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO) supporting clinical development of the trial.
Business Wire · 10/16 12:00
Rocket Pharma presents positive update on RP-L201 in LAD-I and RP-L401 for infantile malignant osteopetrosis
Rocket Pharmaceuticals (RCKT) announces positive longer-term follow-up data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I) at the European Society for Immunodeficiencies ((ESID)) 2020 Meeting being
Seekingalpha · 10/16 11:34
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)
Benzinga · 10/16 11:15
Rocket Pharmaceuticals Highlights Presentation Of LAD-l Clinical Update And Comprehensive IMO Preclinical Review At European Society For Immunodeficiencies 2020 Meeting
—Longer-Term Data from the Registration-Enabling Phase 1/2 Trial for Leukocyte Adhesion Deficiency-I Demonstrate Safety and Efficacy of RP-L201— —Preclinical Data From RP-L401 for Infantile Malignant
Benzinga · 10/16 11:04
The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 13)
Benzinga · 10/14 11:53
Here is What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 10/13 17:04
The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12)
Benzinga · 10/13 12:20
The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline
Biotech stocks advanced along with the broader market in the week ended Oct. 9, although the news flow was quite light.
Benzinga · 10/11 17:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCKT. Analyze the recent business situations of ROCKET PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCKT stock price target is 38.40 with a high estimate of 47.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 160
Institutional Holdings: 59.11M
% Owned: 107.10%
Shares Outstanding: 55.19M
TypeInstitutionsShares
Increased
48
2.89M
New
41
1.62M
Decreased
25
3.57M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.36%
Pharmaceuticals & Medical Research
-2.32%
Key Executives
Chairman/Director
Roderick Wong
President/Chief Executive Officer/Director
Gaurav Shah
Chief Financial Officer/Senior Vice President - Finance
Kamran Alam
Chief Operating Officer
Kinnari Patel
Chief Accounting Officer/Controller
John Militello
Other
Jonathan Schwartz
Director
David Southwell
Independent Director
Elisabeth Bjork
Independent Director
Carsten Boess
Independent Director
Pedro Granadillo
Independent Director
Gotham Makker
Independent Director
Naveen Yalamanchi
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.